BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Apr 17, 2006
 |  BioCentury  |  Product Development

Attacking Huntington's disease

Attacking Huntington's disease

Company Product Description Status
Prestwick/ Cambridge Labs Xenazine tetrabenazine Selective inhibitor of vesicular monoamine transporter (VMAT2)

Read the full 121 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >